3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Carcinoma, Renal Cell
2
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hemangioblastoma
1
Glioblastoma
1
Adenoma, Islet Cell
1
Interventions
pentetreotide
1
fludarabine phosphate
1
belzutifan
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
LY2940680
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Biopsy
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
belzutifan
×
CNS
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA